ImmunoGen

YTD

ALL

Why Robinhood?

You can watch ImmunoGen and buy or sell other stocks, ETFs, and their options commission-free!

About IMGN

ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151.

CEO

Mark Joseph Enyedy

CEOMark Joseph Enyedy

Employees

—

Employees—

Headquarters

Waltham, Massachusetts

HeadquartersWaltham, Massachusetts

Founded

1981

Founded1981

Employees

—

Employees—

IMGN Key Statistics

Market cap

8.72B

Market cap8.72B

Price-Earnings ratio

-104.24

Price-Earnings ratio-104.24

Dividend yield

—

Dividend yield—

Average volume

10.88M

Average volume10.88M

High today

—

High today—

Low today

—

Low today—

Open price

—

Open price—

Volume

0.00

Volume0.00

52 Week high

$31.25

52 Week high$31.25

52 Week low

$3.61

52 Week low$3.61

People also own

Based on the portfolios of people who own IMGN. This list is generated using Robinhood data, and it’s not a recommendation.

Plug Power

Inovio

Take-Two Interactive Soft…

GoPro

Ford Motor

Aurora Cannabis